Last updated: February 9, 2021
Sponsor: Instituto Mexicano del Seguro Social
Overall Status: Active - Not Recruiting
Phase
3
Condition
Liver Disease
Gall Bladder Disorders
Primary Biliary Cholangitis
Treatment
N/AClinical Study ID
NCT04751188
R-2020-2101-031
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- PBC diagnosis (consistent with American Association for the Study of Liver Disease [AASLD]:
- History of elevated alkaline phosphatase levels.
- Anti-mitochondrial antibodies positivity
- Histopathologic evidence of nonsuppurative cholangitis and destruction of smallor medium- sized bile ducts.
- Use of ursodeoxycholic acid (UDCA) for at least 12 months at enrollment at atherapeutic dose (13 to 15 mg per Kg per day).
- Evidence of a suboptimal biochemical response to UDCA, defined by the presence of oneof the Paris II criteria.
- Written informed consent.
- Age ≥ 18 years.
Exclusion
Exclusion Criteria:
- Hepatic decompensation (ascitis, variceal upper gastrointestinal bleeding, hepaticencephalopathy).
- Coexistence autoimmune hepatitis.
- Bilirrubin >3mg/dl.
- For females, pregnancy or breast-feeding.
- Hepatocellular carcinoma.
- History or presence of spontaneous bacterial peritonitis.
Study Design
Total Participants: 11
Study Start date:
October 02, 2020
Estimated Completion Date:
July 31, 2021
Connect with a study center
Instituto Mexicano de Seguro Social
Puebla, 72000
MexicoSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.